The inhibition of low density lipoprotein oxidation by 17-alpha estradiol

R. Dittrich; A. Müller; J. Hensen; L. Wildt

doi:10.1055/s-0029-1212073

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 1999; 107(1): 53-57
DOI: 10.1055/s-0029-1212073

Article

The inhibition of low density lipoprotein oxidation by 17-alpha estradiol

R. Dittrich¹ , A. Müller¹ , J. Hensen² , L. Wildt¹

¹Division of Gynaecological Endocrinology and Reproductive Medicine, Dept. of Obstetrics and Gynaecology, University of Erlangen-Nuremberg, Erlangen, Germany
²Division of Endocrinology, Dept. of Medicine I, University of Erlangen-Nuremberg, Erlangen, Germany

Abstract

als PDF herunterladen

Summary

The inhibition of LDL-oxidation by 17-alpha estradiol was assessed in vitro by the determination of the duration of the lagphase in copper ion-induced oxidation and compared to that of 17-beta estradiol, estriol, and probucol. Addition of 0.2, 0.4, and 1 umol/1 of the test substances prolonged the lag-phase of LDL-oxidation 1.3-(±0.09 SD), 1.7-(±0.14 SD), and 2.7-(±0.25 SD) fold for 17-alpha estradiol; 1.4-(±0.14 SD), 1.8-(±0.1 SD), and 2.6-(±0.16 SD) fold for 17-beta estradiol; 1.1-(±0.07 SD), 1.4-(±0.11 SD), and 1.6-(±0.11 SD) fold for estriol as well as 1.4-(±0.14 SD), 1.6-(±0.1 SD), and 3.0-(±0.21) fold for probucol, thus proving that 17-alpha estradiol is as effective as 17-beta estradiol or similar to probucol and more effective than estriol (n = 6 in all cases). These data demonstrate that 17-alpha estradiol is able to delay LDL-oxidation, hence providing a basis for clinical examination of the protective effects of 17-alpha estradiol against atherosclerosis in patients where hormonal effects of 17-beta estradiol are undesirable.

Key words

LDL oxidation - 17-alpha estradiol - antioxidants - atherosclerosis

PDF (77 kb)